


=>

Uploading C:\Program Files\Stnexp\Queries\10566149-broad.str



chain nodes :

20 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

5-9 15-20 17-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17  
14-15

15-16 16-17

exact/norm bonds :

5-9 13-14 13-17 14-15 15-16 15-20 16-17 17-21

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 : 13 :

Connectivity :

21:2 E exact RC ring/chain


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:CLASS  
21:CLASS

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10566149-narrow-1.str



chain nodes :

13 14 16 17 18

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

```

chain bonds :
5-9  7-14  10-13  14-16  16-17  17-18
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-11  8-9  9-10  10-11
exact/norm bonds :
5-9  7-8  7-11  7-14  8-9  9-10  10-11  10-13  14-16  16-17  17-18
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 :

```

```

Connectivity :
14:2 E exact RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:CLASS


```

L4        STRUCTURE UPLOADED

```

>
Uploading C:\Program Files\Stnexp\Queries\10566149-narrow-2.str

```



```

chain nodes :
8  10  11  12  13  14
ring nodes :
1  2  3  4  5  6
chain bonds :
5-8  8-10  10-11  11-12  12-13  12-14
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
5-8  8-10  10-11  11-12  12-13  12-14
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :

```

```

Connectivity :
8:2 E exact RC ring/chain  11:2 E exact RC ring/chain
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  8:CLASS  10:CLASS  11:CLASS
12:CLASS
13:CLASS  14:CLASS


```

L7        STRUCTURE UPLOADED

L1                   STRUCTURE UPLOADED  
 L3           1028 S L1 SSS FULL  
 L4                   STRUCTURE UPLOADED  
 L6           805 S L4 SSS FULL SUB=L3  
 L7                   STRUCTURE UPLOADED  
 L9           12 S L7 SSS FULL SUB=L6  
 L11           4 S L9  
 L12           1 S US200!-566149/APPS  
 L13           1 S L11 AND L12  
 L16           3 S L11 NOT L12


FILE 'REGISTRY' ENTERED AT 14:50:52 ON 08 MAY 2008

=> d 11  
 L1 HAS NO ANSWERS  
 L1                   STR



Structure attributes must be viewed using STN Express query preparation.

=> d 14  
 L4 HAS NO ANSWERS  
 L4                   STR








Structure attributes must be viewed using STN Express query preparation.

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:120905 CAPLUS <<LOGINID::20080508>>

DN 142:219267  
 TI Preparation of biphenyloxazolidinones and related compounds for treatment  
 of infection, proliferative disease, inflammation, and gastrointestinal  
 mobility disorders.  
 IN Oyelere, Adegboyega K.; Goldberg, Joel A.; Orbin, Alia; Salvino, Joseph  
 M.; Zhou, Jiacheng  
 PA Rib-X Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012270	A2	20050210	WO 2004-US24334	20040728
	WO 2005012270	A3	20060112		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1664001	A2	20060607	EP 2004-779400	20040728
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	JP 2007500707	T	20070118	JP 2006-522027	20040728
	US 20050203147	A1	20050915	US 2005-118808	20050429
	US 7148219	B2	20061212		
	US 20060264426	A1	20061123	US 2006-486769	20060714
	US 20070197541	A1	20070823	US 2007-566149	20070418 <--
PRAI	US 2003-490855P	P	20030729		
	US 2003-475430P	P	20030603		
	US 2003-475453P	P	20030603		
	US 2003-529731P	P	20031215		
	US 2003-531584P	P	20031219		
	US 2004-859476	A1	20040602		
	WO 2004-US24334	W	20040728		
	US 2005-118808	A1	20050429		
OS	CASREACT 142:219267; MARPAT 142:219267				
GI					



AB MXLA(R1)mB(R2)nQ [A, B = Ph, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl; Q = Q1-Q4; M = Q5L1C(:W)L2; L1, L2 = bond, (R4-substituted) alkyl; Q5 = H, N(R4)2, OR4, (R4-substituted) alkyl; W = O, S; X = NR4, NR4NR4, S; L = (R4-substituted) alkyl; R1, R2 = F, Cl, Br, iodo, CF3, cyano, NO2, OR7, N(R7)2, COR7, CO2R7, CON(R7)2, etc.; R3 = OR7, N(R7)2, COR7, CO2R7, CON(R7)2, etc.; R4 = H, :O, :S, NR5, NOR5, :NN(R5)2, OR5, NO2, N(R5)2, etc.; R5 = H, (substituted) alkyl, alkylcarbonyl, alkoxy carbonyl; R6 = OH, alkoxy, SH, NO2, NH2, etc.; R7 = H, (substituted) alkyl, alkenyl alkynyl, (unsatd.) carbocyclyl, heterocyclyl, etc.; m, n = 0-4], were prepared as drugs (no data). Thus, title compound (I) was prepared in several steps from N-[3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 4-hydroxymethylphenylboronic acid, and bromoacetamide.

=> d 116 tot bib abs hitstr

L16 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:226910 CAPLUS <<LOGINID::20080508>>  
 DN 146:295903  
 TI Preparation of oxazolidinones possessing antimicrobial activity and pharmaceutical compositions thereof  
 IN Sindkhedkar, Milind D.; Bhavsar, Satish B.; Patil, Vijaykumar J.; Deshpande, Prasad K.; Patel, Mahesh V.  
 PA Sindkhedkar, Milind, D., India; Bhavsar, Satish, B.; Patil, Vijaykumar, J.; Deshpande, Prasad, K.; Patel, Mahesh, V.  
 SO PCT Int. Appl., 210 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007023507	A2	20070301	WO 2006-IN208	20060619
	WO 2007023507	A3	20070712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW



RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

IN 2005MU00723 A 20070706 IN 2005-MU723 20050620  
 EP 1912980 A2 20080423 EP 2006-821680 20060619

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRAI IN 2005-MU723 A 20050620  
 WO 2006-IN208 W 20060619

OS MARPAT 146:295903  
 GI




AB Title compds. I [R1 = OH, formamide, (un)substituted amine, etc.; X and Y independently = CH, CF or N; Q = (un)substituted heterocyclyl, heteroaryl, aryl, etc.], and their pharmaceutically acceptable salts, were prepared and disclosed as having antimicrobial activity. Thus, e.g., II was prepared by reduction of the corresponding oxopiperidine derivative (preparation given).

Several

microbial assays are described, e.g., selected I displayed antibacterial activity for *Staphylococcus aureus* ATCC 25923 equal to 0.5 to  $\geq 8$  mg/mL. Thus, the present invention provides novel oxazolidinone derivs., processes for making compds. as well as antimicrobial pharmaceutical compns. containing said derivs. as active ingredients and methods of treating microbial infections with the said derivs.


IT 928159-76-6P 928159-78-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of oxazolidinones possessing antimicrobial activity and  
 pharmaceutical compns. thereof)  
 RN 928159-76-6 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3'-[[[(2-amino-2-oxoethyl)amino]methyl]-2-  
 fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 928159-78-8 CAPLUS  
 CN Acetamide, 2,2'-[[[4'-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-  
 2'-fluoro[1,1'-biphenyl]-3-yl]methyl]imino]bis- (CA INDEX NAME)

Absolute stereochemistry.




DN 144:274261  
 TI Preparation of 3-biphenyl-2-oxazolidone derivatives as antiinfective agents  
 IN Lou, Rongliang; Bhattacharjee, Ashoke; Chen, Yi; Chen, Shili; Adegboyega, Oyelere K.; Wang, Deping; Wu, Yusheng; Zhou, Jiacheng  
 PA Rib-X Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006022794	A1	20060302	WO 2004-US39966	20041201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1778653	A1	20070502	EP 2004-812487	20041201
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008508271	T	20080321	JP 2007-523532	20041201
PRAI	US 2004-591771P	P	20040728		
	WO 2004-US39966	W	20041201		
OS	CASREACT 144:274261; MARPAT 144:274261				
AB	The title 3-biphenyl-2-oxazolidone derivs. with general formula of M-L-A(R1)m-D(R2)n-Het-CH2-R3 [wherein m and n = independently 0-4; A and D = independently Ph, pyridyl, pyrazinyl, pyrimidinyl, or pyridazinyl; Het = disubstituted 2-oxazolidinone, 5(2H)-isoxazolone, isoxazoline, or 2,5-dihydrofuranone; M = CN, alkyl, (un)substituted alkenyl, alkynyl, etc.; L = bond, -O-, -NH-, =N-O-, etc.; R1 and R2 = independently halo, CF3, CN, OH, NO2, NH2, etc.; R3 = independently OH, CF3, NH2, CO2H, etc.], or pharmaceutically acceptable salts, esters, or prodrugs thereof were prepared For example, (5S)-N-[3-[4'-(amino-cyanomethyl)-2-fluorobiphenyl-4-yl]-2-oxo-oxazolidin-5-ylmethyl]acetamide was prepared in a multi-step synthesis. The title compds. are useful as anti-infective, anti-proliferative, and anti-inflammatory agents (no data).				
IT	877876-03-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of 3-biphenyl-2-oxazolidone derivs. as antiinfective agents)				
RN	877876-03-4	CAPLUS			
CN	Acetamide, N-[[[(5S)-3-[4'-[[[(2-amino-2-oxoethyl)(cyanomethyl)amino]methyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)				

Absolute stereochemistry.








RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:120906 CAPLUS <<LOGINID::20080508>>  
DN 142:219289  
TI Process for the synthesis of biaryl oxazolidinones  
IN Wu, Yusheng; Chen, Shili; Chen, Yi; Hanselmann, Roger; Lou, Rongliang;  
Zhou, Jiacheng  
PA Rib-X Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 110 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012271	A2	20050210	WO 2004-US24339	20040728
	WO 2005012271	A3	20050929		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050043317	A1	20050224	US 2004-859476	20040602
	US 6969726	B2	20051129		
	EP 1660465	A2	20060531	EP 2004-779405	20040728
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2007500708	T	20070118	JP 2006-522029	20040728

	US 20050203147	A1	20050915	US 2005-118808	20050429
	US 7148219	B2	20061212		
	US 20060148869	A1	20060706	US 2006-362133	20060223
	US 20060264426	A1	20061123	US 2006-486769	20060714
PRAI	US 2003-490855P	P	20030729		
	US 2003-529731P	P	20031215		
	US 2003-530371P	P	20031217		
	US 2003-531584P	P	20031219		
	US 2004-576163P	P	20040602		
	US 2004-859476	A	20040602		
	US 2003-475430P	P	20030603		
	US 2003-475453P	P	20030603		
	US 2004-576267P	P	20040602		
	WO 2004-US24339	W	20040728		
	US 2004-1446	A3	20041201		
	US 2005-118808	A1	20050429		
OS	CASREACT 142:219289; MARPAT 142:219289				
GI					



AB The present invention relates to processes for the preparation of biaryloxazolidinones (I) [A, B = Ph, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl; Het-CH<sub>2</sub>-R<sub>3</sub> = Q<sub>1</sub>, Q<sub>2</sub>, Q<sub>3</sub>, Q<sub>4</sub>; M-L = M-X, M-L<sub>1</sub>, M-L<sub>1</sub>-X, M-X-L<sub>2</sub>, M-L-X-L<sub>2</sub>, M-X-L<sub>1</sub>-X-L<sub>2</sub>, M-L<sub>1</sub>-X-L<sub>2</sub>-X, M-X-X-, M-L<sub>1</sub>-X-X-, M-X-X-L<sub>2</sub>, -L<sub>1</sub>-X-X-L<sub>2</sub>; wherein X = -, (un)substituted NH, -N(OH)-, -SO<sub>2</sub>NH-, -NHSO<sub>2</sub>-, -NH-N=, =N-NH-, -NH-NH-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH- or -NHC(NH)NH-, -O-N=, =N-O-, -N=, =N-, etc.; L<sub>1</sub>, L<sub>2</sub> = each (un)substituted C<sub>1</sub>-6 alkyl, C<sub>2</sub>-6 alkenyl, or C<sub>2</sub>-6 alkynyl; alternatively, L in M-L is a bond and M = each (un)substituted C<sub>3</sub>-14 saturated, unsatd., or aromatic carbocycle, 3-14 membered saturated, unsatd., or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S, C<sub>1</sub>-6 alkyl, C<sub>2</sub>-6 alkenyl, or C<sub>2</sub>-6 alkynyl, cyano; R<sub>1</sub>, R<sub>2</sub> = F, Cl, Br, iodo, CF<sub>3</sub>, each (un)substituted OH, NH<sub>2</sub>, CO<sub>2</sub>H, or CONH<sub>2</sub>, cyano, NO<sub>2</sub>, etc.; R<sub>3</sub> = each (un)substituted OH, NH<sub>2</sub>, CO<sub>2</sub>H, CONH<sub>2</sub>, NHCONH<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, etc.; m, n = 0-4] which comprises coupling of the compound of formula (II) (Q = borane having the formula BY<sub>2</sub>; Y = HO, C<sub>1</sub>-6 alkoxy, C<sub>2</sub>-6 alkenyloxy, C<sub>2</sub>-6 alkynyloxy, etc.) with the compound of formula (III) (Z = iodo, Br, Cl, sulfonate). These compds. I are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents (no data). Thus, [4-[[N-(3-fluoropropyl)-N-(tert-butylcarbonyl)amino]methyl]phenyl]boronic

acid and (5S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide were stirred with tetrakis(triphenylphosphine)palladium (0) and K<sub>2</sub>CO<sub>3</sub> in a mixture of toluene, ethanol, and water at reflux for 8 h to give (5S)-[[4'-[5-[(acetylamino)methyl]-2-oxooxazolidin-3-yl]-2'-fluorobiphenyl-4-yl]methyl](3-fluoropropyl)carbamic acid tert-Bu ester which was stirred with HCl/1,4-dioxane at room temperature for 12 h to give (5S)-N-[[3-[2-fluoro-4'-[(3-fluoropropylamino)methyl]biphenyl-4-yl]-2-oxooxazolidin-5-yl]methyl]acetamide monohydrochloride (IV).

IT 843647-33-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(process for synthesis of biaryloxazolidinones by Suzuki coupling reaction of arylboronic acids with aryl halides or sulfonates)

RN 843647-33-6 CAPLUS

CN Acetamide, N-[[ (5S)-3-[4'-[1-[(2-amino-2-oxoethyl)amino]ethyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

